CG Oncology Accelerates Phase 3 Bladder Cancer Trial Data Readout, Reports Strong Clinical Results

summarizeSummary

CG Oncology announced an expedited timeline for its PIVOT-006 Phase 3 trial data, now expected nearly a year early, alongside positive clinical results from two other bladder cancer studies, highlighting strong progress for its lead immunotherapy candidate.

check_boxKey Events

• Accelerated Phase 3 Data

  Topline data for the PIVOT-006 Phase 3 trial in intermediate-risk NMIBC is now expected in the first half of 2026, nearly one year ahead of schedule, indicating rapid trial progress.

• Positive BOND-003 Cohort P Results

  Cretostimogene monotherapy showed encouraging High-Grade Event-Free Survival (HG-EFS) rates (95.7% at 3 months, 80.4% at 9 months) and a well-tolerated safety profile in BCG-unresponsive papillary-only NMIBC.

• Promising CORE-008 Cohort A Data

  Cretostimogene monotherapy achieved an 83.7% overall complete response rate in high-risk, BCG-naïve NMIBC with CIS, with a favorable safety profile and no Grade 3+ adverse events.

auto_awesomeAnalysis

CG Oncology announced a significant acceleration of its PIVOT-006 Phase 3 clinical trial, with topline data for intermediate-risk non-muscle invasive bladder cancer (IR NMIBC) now expected nearly a year ahead of schedule in the first half of 2026. This expedited timeline for a potential first-in-class therapy in a large patient population is a major positive catalyst, suggesting rapid trial enrollment and potentially strong progress. Additionally, the company reported encouraging topline results from its BOND-003 Cohort P trial in BCG-unresponsive papillary-only NMIBC, demonstrating high High-Grade Event-Free Survival (HG-EFS) and a favorable safety profile. Further positive data from CORE-008 Cohort A in high-risk, BCG-naïve NMIBC with CIS showed an impressive complete response rate and good tolerability. These updates collectively reinforce the strong clinical profile and broad potential of cretostimogene across multiple bladder cancer indications, significantly de-risking the pipeline and accelerating its path to market.